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Severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2)  has 
affected millions of people across the world engendering an unprecedented 
pandemic.  Coronavirus disease (COVID)-19 can present asymptomatic 
or in the form of the acute respiratory syndrome, viral pneumonia,or 
sepsis. Due to the novelty of the disease, the endocrine manifestations are 
not fully understood. It becomes indispensable to address the underlying 
endocrine disruptions contributing to the severe form of illness and thereby 
increasing the mortality.We discuss here the SARS-CoV-2 virus and 
endocrine reverberations based on the research with structurally similar 
SARS-COV-1. SARS-CoV-2 enters the body via its attachment to the 
angiotensin-converting enzyme 2 (ACE2) receptors. Apart from lungs, 
ACE2 expression on various organs can lead to endocrine perturbations. 
In COVID-19 infection, pre-existing endocrine disorders warrant cautious 
management and may require replacement therapy. COVID-19  and its 






Severe acute respiratory syndrome coronavirus 
(SARS-CoV)-2
1. Introduction
The coronavirus disease (COVID)-19 pandemic caused 
by the  novel  severe acute  respiratory syndrome corona 
virus (SARS-CoV)- 2 has led to worldwide havoc and a 
significant impact on psychological wellbeing. In March 
2020, the  World Health Organisation (WHO) declared 
COVID-19 a global pandemic. The existing data suggest 
that stress and anxiety have doubled during this pandemic. 
Psychological and physiological stress increases serum 
cortisol levels along with its bioavailability by stimulation 
of the hypothalamic-pituitary-adrenal axis, decreasing 
the number of cortisol-binding globulin, and its metabo-
lism [1,2]. Increased cortisol level is an integral response to 
stress, activating adaptive changes in the immune system, 
metabolism, and cardiovascular function. Patients  with 
Diabetes mellitus  are considered to be  under  the high-
risk category for having serious illness modality in case 
of contact with COVID-19 infection. Furthermore, other 
endocrine diseases such as adrenal insufficiency, mal-
nutrition, and obesity can also be strongly impacted by 
COVID-19 [3,4].
2. Methods
It is well known that COVID 19 can produce a lot of 
stress; nevertheless, how much could this stress produce 
changes in our hormones? Keeping this research question 
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in mind, we did a literature search using the key words 
COVID-19, SARS-CoV-2, SARS-CoV-1, endocrine, hor-
mones, and related terms in the medical databases includ-
ing Google Scholar, MedARXiv, PubMed, Cochrane and 
Web of Science databases. In addition to these, references 
were spotted through a manual search of bibliographies 
and via the citations in the articles. COVID-19 infection 
and its repercussions on hormones are discussed exten-
sively in this review. This review tries to address the effect 
of the stress response on hormones and its catastrophic 
effect on the COVID-19 patient.
2.1 Epidemiology
The outbreak of COVID-19 in Wuhan is speculated 
to be associated with wild animals. According to WHO, 
Wuhan seafood market environmental samples were test-
ed positive for SARS-CoV-2 and it is suggested that bats 
may be the origin of COVID-19 (the host of more than 
30 coronaviruses) [5,6]. The bats are considered the natural 
reservoir of SARS-CoV and MERS-CoV, and spread to 
humans [7]. The short RNA-dependent RNA polymerase 
(RdRp) region (RaTG13) from a bat coronavirus, was 
nearest to SARS-CoV-2 with an identity of 96.2-98.7% in 
whole-genome sequence [8-11].
The mean incubation period is around 5.2 days. A 
research in Wuhan on 85 serious patients (median age 
65yrs) concluded that most of the mortality was due to 
multi-organ failure such as respiratory failure( 94%), acute 
respiratory distress syndrome (ARDS(74%) and shock 
(81%) [12]. In parallel to this high prevalence of multiorgan 
failure, a high level of D-dimer, fibrinogen, and prolonged 
thrombin time have also been observed in severe forms of 
the disease [13].
2.2 Pathogenesis
Coronaviruses are single-stranded ribonucleic acid 
(RNA) (30kb), positive-sense, and enveloped viruses, 
infecting various host species [14]. They are broadly di-
vided into four genera based on their genomic structure; 
alpha, beta, gamma, and delta. Alpha and beta coronavi-
rus causes infection in mammals only [15]. SARS-CoV-2 
are classified as beta coronaviruses. The pathogenesis 
of COVID-19 entails the entry of inhaled SARS-CoV-2 
virus and binding to the epithelial cells in the nasal cav-
ity causing replication. After entering the respiratory 
system,it lodges in the lung parenchyma and interacts 
with angiotensin-converting enzyme(ACE)- 2 receptor to 
ingress into host pneumocytes. The plasma or serum of 
COVID-19 patients has demonstrated viral RNA showing 
viremia [16], this implicits that the virus is also available 
free to interact with ACE2 expressed in various tissues and 
a number of endocrine organs including the thyroid, pitu-
itary, pancreas, adrenal glands, testis, and ovary [17].
2.3 COVID-19 and its effects on Different on En-
docrine Organs
2.3.1 Pituitary gland
Alteration in the function of the pituitary in severe acute 
respiratory syndrome (SARS) was first documented by 
Leow et al. [18] An evaluation of 61 patients who survived 
the SARS outbreak found evidence of central mild hypo-
cortisolism (40%) and hypothyroidism (5%) [18]. Hypotha-
lamic and pituitary tissues both express ACE2 and could 
be the vital target in the case of COVID-19 [19]. COVID-19 
patients with pituitary-hypothalamic disorders usually 
have diabetes insipidus (DI) that can cause insensible wa-
ter loss due to fever eventually resulting in hypernatremia 
[20], requiring extra precautions. Dopamine synthetic path-
ways alteration has also been implicated in the pathophys-
iology of COVID-19 [21].
Anterior pituitary cells have illustrated changes in 
biopsy of SARS-CoV patients [22]. The number of corti-
cotrophs,thyrotrophs,and somatotrophs was decreased and 
vice-versa was seen in the number of gonadotrophs and 
lactotrophs. These results correspond with biochemical 
abnormalities of an increased level of luteinising, follicle 
stimulating hormone, and prolactin as reported in Chinese 
literature earlier [23].
Postviral cataclysm:
Postviral syndrome manifests as low moods, low en-
ergy level, and dizziness. It is associated with hypocorti-
solism ( postviral) and it enormously improves with cor-
tisol replacement [24]. Furthermore, the interaction of ACE 
receptors with the neurotransmitter pathways could lead 
to idiopathic chronic fatigue syndrome and chronic fatigue 
[24,25]. This effect has been suggested to be mediated by 
deletion/insertion polymorphisms in the ACE gene cod-
ing for its receptor [25]. Disruption of the ACE2 receptors 
expressed in the hypothalamus, may play a pivotal role in 
hypocortisolism and post-viral fatigue [26,27].
It has been observed that the entry of the SARS-CoV in 
the brain is via the ACE2 receptors seated in the olfactory 
bulb causing ageusia and anosmia [28]. It is attributed to a 
central or local pathway leading to hormonal deficiencies 
due to the damage to the hypothalamus [29].
2.3.2 Prolactin
Hyperprolactinemia is considered as a repercussion in 
response to sepsis or infection [30]. Increased prolactin lev-
els have been demonstrated in severe respiratory infection 
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in infants and severe sepsis [31,32]. As of now, no data are 
available in patients with hyperprolactinemia on having 
susceptibility to infection.
2.3.3 Thyroid
A research conducted on SARS-CoVsurvivors for 
any hormonal derangements three months after recovery 
found that 6.7% of the patients had developed biochem-
ical hypothyroidism [24], out of which 75% had a central 
etiology and 25% had positive antibodies with primary 
hypothyroidism. Also, thyroid hormone replacement was 
continued at the end of the study. Alterations in the thyroid 
profile on the follow-up of central hypothyroidism were 
found to be normalised. The authors suggested monitoring 
of thyroid function tests during active and convalescence 
period of SARS-CoV-2 disease, also suggesting replace-
ment therapy if needed [24].
A research conducted on forty-eight SARS-CoV1 
infected patients demonstrated decreased triiodothy-
ronine(T3) (94%), thyroxine (T4) (46%) along with 
reduced serum thyroid stimulating hormone (TSH), con-
sidering the possibility of either the sick euthyroid syn-
drome or central hypothyroidism [33]. A follow-up study of 
sixty-one SARS patients inspecting endocrine disorders, 
found 2 cases of subclinical thyrotoxicosis, 3 cases with 
central hypothyroidism, and 1 patient with primary hy-
pothyroidism with positive thyroid autoantibodies [24]. 
Significantly low levels of TSH and free T3 were found in 
deceased patients when compared to recovered patients in 
a report of 274 patients [34].
Different effects of acute illness have been observed on 
the thyroid axis (Figure1) along with down-regulation of 
the hypothalamo-pituitary axis [35].
The British Thyroid Association and the Society for En-
docrinology have passed a consensus statement regarding 
thyroid dysfunction during COVID-19 pandemic [36]. Pa-
tients with underlying hyperthyroidism and hypothyroid-
ism are guided to pursue their medications as prescribed. 
In hyperthyroid patients on antithyroid drugs, agranulo-
cytosis should be kept in mind, although the prevalence is 
rare (0.2%-0.5%) [36]. Agranulocytosis symptoms such as 
sore throat, fever are congruent with those of COVID-19 
and it is imperative to get a complete blood count to as-
certain the possibility of agranulocytosis.
A histopathological study of the thyroid gland on the 
effects of SARS infection found immense injury to the 
follicular and parafollicular cells. Parafollicular cells are 
responsible for the production of calcitonin. Osteonecrosis 
of the femoral head in SARS recovered patients was at-
tributed to it as a possible mechanism [37].
2.3.4 Adrenal Gland
A primary immunological strategy employed by the 
SARS-CoV is to blow down the cortisol stress response 
Figure 1. Acute phase effects on the thyroid axis [35]
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in the host. It has been suggested that there is a possibility 
that the expression of few amino acid sequences by the 
SARS-CoV that are a molecular imitation of the host ad-
renocorticotropic hormone (ACTH) can obtund the stress 
induced rise in cortisol level and the antibodies produced 
against the virus can inadvertently demolish the circulat-
ing ACTH [38].
Ding et al. demonstrated the histological changes in the 
adrenal gland from the post-mortem biopsies of patients 
dying from SARS-CoV. The author found mainly lympho-
cytes and monocytes infiltrating the adrenal medulla [39].
 Homogeneity of the SARS-CoV2 proteins with the 
SARS-CoV might mimic the same molecular strategy, 
thus making severe COVID-19 patients vulnerable to 
develop critical illness- correlating corticosteroid insuf-
ficiency [40]. Furthermore, clinicians must be cautious 
regarding the underlying relative cortisol deficiency in 
COVID-19 patients. Primary adrenal insufficiency (PAI) 
patients are at high risk of respiratory tract infections. 
There is a need for glucocorticoid support in PAI with 
COVID-19; nevertheless,hypokalaemia has been reported 
in these patients [41].
2.3.5 Endocrine Pancreas
Coronavirus enters the pancreas by interacting with the 
ACE2 receptors. ACE2 receptors are expressed more in 
the endocrine pancreas in comparison to pancreatic exo-
crine tissues [42]. 51% of SARS-CoV patients have been 
found to have developed new-onset diabetes with no his-
tory of diabetes or receival of any steroid treatment during 
the illness [42]. Pancreatic exocrine injury is manifested 
as an increased level of biochemical markers, raised am-
ylase (1-2%) and lipase (17%) in severe or non-severe 
COVID-19 [17]. SARS-CoV facilitated injury of the pan-
creas ( beta cells ) was suggested as the feasible theory 
behind acute diabetes in this subset of patients [43].
Pro-inflammatory mileu, as explicit by increased 
interleukin, inducible protein-10, interleukin-1β, mono-
cyte chemo-attractant protein-1 (MCP-1), even in mild 
COVID-19 may play a pivotal role in the foreground pro-
cess [44]. Poor glycaemic control is an independent marker 
of increased mortality and morbidity in SARS-CoV pa-
tients with or without history of diabetes mellitus [45].
Insulin resistance can be accentuated in COVID-19 
patients with pre-existing Type2 DM. This is further ac-
centuated due to COVID-19 treatment drugs. Ritonavir/
Lopinavir produce further insulin resistance and lipodys-
trophy. Down-regulation of ACE2 levels and decreased 
innate immunity could be the possible mechanisms re-
sponsible for severe disease and acute respiratory distress 
syndrome (ARDS) in DM with COVID-19 patients [46]. 
Hypokalaemia produces downregulation of pulmonary 
ACE2 receptors, subsequent increase in aldosterone secre-
tion and this can further deteriorate the glucose control in 
pre-existing Type 1and 2 DM patients [46] (Figure 2).
Figure 2. Hypokalaemia in COVID-19
The susceptibility of cytokine storm is exacerbated 
in patients with diabetes leading to rapid deterioration, 
as evidenced by the high level of biomarkers,interleu-
kin-6(IL-6), C-reactive protein, serum ferritin, and D-di-
mer [17]. In a few post-mortem reports, hydropic degenera-
tion, interstitial proliferation, and fatty degeneration have 
been found to be indicators of pancreatic injury [47].
2.3.6 Androgens
A high level of ACE2 expression in the human testis 
has been analysed, demonstrating testis to be a high-
risk organ susceptible to SARS-CoV2 infection [48,49]. In 
a neo- study, ACE2 has been found to be expressed in 
somatic (Sertoli and Leydig) and spermatogonia cells 
in the testis [50]. Transmembrane protease serine 2 (TM-
PRSS2)expressed in spermatogonia and spermatids is also 
expressed in the pulmonary level. Furthermore, TMPRSS2 
inhibitors used for prostate cancer, may present an effec-
tive target for the prevention or treatment of COVID-19 
pneumonia [51]. Also, poor outcomes of COVID-19 in 
males might be due to a high level of co-morbidities, hy-
pertension, lung disease, and cardiovascular comorbidity. 
Serum testosterone levels require cautious interpretation 
in COVID-19 patients, as acute critical illness can cause 
suppression of the hypothalamic-pituitary-testicular axis, 
manifesting biochemically as decreased luteinizing hor-
mones (LH), follicle -stimulating hormone (FSH) and 
testosterone(T). Serum T:LH ratio was found lower in 
COVID-19 patients and was negatively associated with 
the severity of the disease52. In a study, 81 COVID-19 
males exhibited lower total serum testosterone and higher 
serum LH, when compared to healthy males [52]. In an au-
DOI: https://doi.org/10.30564/jer.v2i2.2581
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topsy-based study on males who died of SARS-CoV-1, or-
chitis was demonstrated in all the patients with markedly 
thickened basement membrane, germ cell destruction and 
leukocyte infiltration thus suggesting immune-mediated 
damage rather than viral entry and direct damage [53].
Polycystic ovarian syndrome (PCOS) is the most fre-
quent endocrine disorder among the reproductive age 
group women54. Although the median age affecting the 
female suffering from PCOS is considered at low risk of 
COVID-19, the patients with  associated  comorbid condi-
tions including obesity and  metabolic disorders are prone 
to develop severe symptoms of COVID-19. Overlap of 
symptoms commonly associated with PCOS and risk 
factors identified for severe COVID-19, seem to enhance 
the severity of the SARS-CoV2 symptoms. Albeit, further 
research is necessary to elicit the direct potential relation 
between the factors increasing metabolic-cardiac risk 
in PCOS e.g hyper-androgenemia, hyper-cytogenemia, 
vitamin- D deficiency and COVID-19 related adverse out-
come [54].
2.4 COVID-19 and Renin -Angiotensin Aldoste-
rone System (RAAS)
RAAS plays a pivotal role in the regulation of blood 
pressure and fluid balance [55]. The final product, angioten-
sin II of the RAAS,is a main vasoactive hormone, bind-
ing angiotensin II receptors type I (AT-1) located in the 
heart,blood vessels, kidney and adrenal gland. It thereby, 
plays a vital role in the inflammation, myocardial hyper-
trophy, fibrosis,and vascular remodelling. 
Few researchers have suggested that down-regulation 
of ACE2 receptors due to SARS-CoV-2 infection can 
conduce secondary damage to the cardiac, lung,and other 
tissue injuries because of the presence of ACE2 in these 
organs. ACE2 convert angiotensin II causing vasodilata-
tion and acting as counter-regulation of the blood pressure 
elevation [56]. Hypertension seems to magnify the inflam-
mation silhouette in the inflammatory silhouette in SARS-
C0V-2 infection, deducing that hypertension may intensi-
fy the risk for a severe illness. Furthermore, these patients 
already have an increased level of inflammatory biomark-
ers such as TNF-, IL-6. Nonetheless, more research is 
needed to elucidate the pathophysiology and eventually 
associated risk in patients having resistant hypertension 
and COVID-19 [57].
The interplay between ACE deletion and insertion 
polymorphism can be correlated with the severity of 
ARDS [58,59]. ACE-2 alleviates inflammation, fibrosis and 
pulmonary hypertension in the lungs, in addition to the in-
hibition of tumor angiogenesis and cancer cell growth [60,61].
2.4.1 ACE-2 Expression in the Blood Vessels
ACE-2 expression in the small and large blood vessels 
produces angiotensin (1-7) [62,63] thereby causing vasodila-
tation, thrombotic and anti-inflammatory effects [62]. Dis-
seminated intravascular coagulation (DIC) and elevation 
of D-dimer (plasma) are observed with severely infected 
COVID-19 infections [64,65]. Furthermore, organ injury in 
COVID-19 can be attributed to increased permeability, 
microcirculation disruption, activation of coagulation cas-
cade, and damage of the vascular endothelium integrity 
due to viral infection and inflammatory response.
2.4.2 Hypocalcemia and COVID-19
Intracellular calcium signalling plays a crucial part 
in the replication and cellular outcome of certain virus-
es [66]. Although in the milieu of COVID-19, the role of 
intracellular calcium signaling is still to be explicated 
and requires further research, Past research suggests that 
hypocalcemia is common in SARS infection [67]. More-
over, COVID-19 infection has been associated as a pre-
cipitating cause of hypoparathyroidism post-surgically 
with severe hypocalcemia [68]. In a retrospective study 
of 531 COVID-19 patients,hypocalcemia was suggested 
in 80% cases on initial evaluation in hospital. Albeit, no 
data on ACE-2 expression, inflammation, or alteration in 
parathyroid function or calcium homeostasis have been 
reported during COVID-19 infection and hence require 
further research. The role of Vitamin-D as a tool in the 
armamentarium of COVID-19 has been shown to enhance 
innate immunity (cellular) partially through antimicrobial 
peptide induction and help in reducing the pro-inflamma-
tory cytokine expression which can be indeed beneficial 
in COVID-19 [69,70].
3. Conclusion
 The endocrine system can be severely affected by the 
SARS-CoV infection in a multitude of ways and data on 
this is still evolving. Amidst the ongoing pandemic, a high 
index of suspicion for endocrinal involvement and an en-
deavour to detect and manage newly emerging endocrine 
entities and alterations in the pattern of pre-existing endo-
crine diseases is of utmost importance. 
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